Ken‐ichi Ito

5.0k total citations
195 papers, 3.6k citations indexed

About

Ken‐ichi Ito is a scholar working on Oncology, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ken‐ichi Ito has authored 195 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Oncology, 40 papers in Surgery and 38 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ken‐ichi Ito's work include Thyroid Cancer Diagnosis and Treatment (32 papers), Liver Disease Diagnosis and Treatment (12 papers) and Cancer-related Molecular Pathways (11 papers). Ken‐ichi Ito is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (32 papers), Liver Disease Diagnosis and Treatment (12 papers) and Cancer-related Molecular Pathways (11 papers). Ken‐ichi Ito collaborates with scholars based in Japan, Canada and United States. Ken‐ichi Ito's co-authors include Roger G. Deeley, Susan P.C. Cole, Jun Amano, Yoshio Yasumura, Masakazu Yamagishi, Maiko Fujimori, Takaaki Oba, Satoshi Nakatani, Kazuma Maeno and Kunio Miyatake and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Ken‐ichi Ito

184 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ken‐ichi Ito Japan	33	1.1k	1.1k	902	763	518	195	3.6k
Keiichi Ito Japan	34	572 0.5×	1.3k 1.2×	932 1.0×	943 1.2×	208 0.4×	349	4.3k
Yukio Ishikawa Japan	42	629 0.5×	1.1k 1.1×	1.2k 1.4×	839 1.1×	181 0.3×	107	4.2k
Toshiyuki Nakayama Japan	35	1.4k 1.2×	1.6k 1.5×	1.0k 1.2×	1.0k 1.3×	149 0.3×	171	4.2k
Tõru Nakamura Japan	35	884 0.8×	1.2k 1.2×	905 1.0×	417 0.5×	196 0.4×	215	3.9k
Fernando Schmitt Portugal	32	1.0k 0.9×	1.1k 1.0×	631 0.7×	565 0.7×	235 0.5×	155	3.6k
Satoru Kawakami Japan	40	985 0.9×	1.5k 1.4×	1.8k 2.0×	2.2k 2.9×	598 1.2×	251	5.1k
Takesada Mori Japan	30	1.0k 0.9×	1.4k 1.3×	1.1k 1.3×	492 0.6×	194 0.4×	158	3.8k
Alberto Smith United Kingdom	40	567 0.5×	1.1k 1.1×	1.1k 1.3×	862 1.1×	274 0.5×	96	4.2k
Anastasios J. Karayiannakis Greece	36	987 0.9×	1.5k 1.4×	1.2k 1.3×	851 1.1×	120 0.2×	112	3.7k
Salvatore Mancuso Italy	40	1.0k 0.9×	1.6k 1.5×	591 0.7×	386 0.5×	151 0.3×	149	5.1k

Countries citing papers authored by Ken‐ichi Ito

Since Specialization

Citations

This map shows the geographic impact of Ken‐ichi Ito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken‐ichi Ito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken‐ichi Ito more than expected).

Fields of papers citing papers by Ken‐ichi Ito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken‐ichi Ito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken‐ichi Ito. The network helps show where Ken‐ichi Ito may publish in the future.

Co-authorship network of co-authors of Ken‐ichi Ito

This figure shows the co-authorship network connecting the top 25 collaborators of Ken‐ichi Ito. A scholar is included among the top collaborators of Ken‐ichi Ito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken‐ichi Ito. Ken‐ichi Ito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Hiroki, et al.. (2025). Characteristics of patients with Graves’ disease who developed drug resistance and required surgery. Endocrine Journal. 72(4). 365–373.

Higashiyama, Takuya, Kiminori Sugino, Hisato Hara, et al.. (2022). Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). European Journal of Cancer. 173. 210–218. 32 indexed citations

Oba, Takaaki, et al.. (2021). The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. Journal of Cancer Research and Clinical Oncology. 147(11). 3211–3224. 14 indexed citations

Onoda, Naoyoshi, Iwao Sugitani, Ken‐ichi Ito, et al.. (2020). Evaluation of the 8th Edition TNM Classification for Anaplastic Thyroid Carcinoma. Cancers. 12(3). 552–552. 27 indexed citations

Onoda, Naoyoshi, Mitsuyoshi Hirokawa, Atsuhiko Sakamoto, et al.. (2019). Factors Influencing the Chemo-Sensitivity of Weekly Paclitaxel for Anaplastic Thyroid Cancer: A Clinico-Pathologic Analysis of Cases Enrolled in a Clinical Trial. 8(1). 1–5. 1 indexed citations

Sugiyama, Yuki, Fumiko Shimizu, Hiroyuki Agatsuma, et al.. (2017). Difficult Management of a Double-Lumen Endotracheal Tube and Difficult Ventilation during Robotic Thymectomy with Carbon Dioxide Insufflation. SHILAP Revista de lepidopterología. 2017. 1–5. 1 indexed citations

Shibata, Tomohiro, Kosuke Watari, Hiroto Izumi, et al.. (2016). Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression. Cancer Research. 77(2). 545–556. 27 indexed citations

Koyama, Hiroshi, Toshihiro Okada, Takayuki Watanabe, et al.. (2011). [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].. PubMed. 38(7). 1123–6. 2 indexed citations

Ito, Ken‐ichi, Tomoyuki Fujita, Kazuma Maeno, et al.. (2007). A CASE OF ANAPLASTIC THYROID CARCINOMA PERFORMED A TOTAL THYROIDECTOMY COMBINED WITH RESECTION OF THE INTRALUMINAL TUMOR THROMBUS IN THE INTERNAL JUGULAR VEIN. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 68(7). 1654–1659.

10.

Ito, Ken‐ichi, Manuel Salto‐Tellez, T. Yano, et al.. (2006). RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization (vol 65, pg 7743, 2005). Cancer Research. 66. 3345–3345. 1 indexed citations

11.

Ito, Ken‐ichi, et al.. (2004). . Journal of the Japanese Society of Revegetation Technology. 29(3). 438–445. 7 indexed citations

12.

Saibara, Toshiji, et al.. (1987). A case of hepatocelluler carcinoma treated with lymphokine-activated killer cells and recombinant interleukin-2.. Kanzo. 28(5). 606–610.

13.

Saibara, Toshiji, et al.. (1986). Monocytotoxic antibodies in primary biliary cirrhosis and its effects on monocyte function.. Kanzo. 27(8). 1105–1111. 1 indexed citations

14.

Miyazaki, Masako, Kazuichi Okazaki, Masanori Morita, et al.. (1986). Measurement of portal blood flow in the patients with obstructive jaundice using a pulsed Doppler system.. Kanzo. 27(11). 1598–1605. 1 indexed citations

15.

Saibara, Toshiji, Takashi Maeda, Saburo Onishi, et al.. (1986). A case of a 80-year-old man with primary biliary cirrhosis complicated with primary hepatocellular carcinona.. Kanzo. 27(4). 497–503. 6 indexed citations

16.

Saibara, Toshiji, et al.. (1985). Defective production of Interleukin 1 and Interleukin 2 in patients with primary biliary cirrhosis.. Kanzo. 26(9). 1183–1187. 1 indexed citations

17.

Saibara, Toshiji, et al.. (1984). . Kanzo. 25(1). 62–66.

18.

K, Ota, H Kawaguchi, Kazuhiro Takahashi, & Ken‐ichi Ito. (1983). A new prostacyclin analogue - an anticoagulant applicable to hemodialysis.. PubMed. 29. 419–24. 8 indexed citations

19.

Suzuki, Hiroshi, Seiichi Furuta, Shiro Iino, et al.. (1983). . Kanzo. 24(9). 955–968. 1 indexed citations

20.

Okazaki, Kazuichi, et al.. (1983). . Kanzo. 24(7). 733–739. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact